Safety of tranexamic acid in total joint arthroplasty for patients with high risk factors of thrombosis: a prospective, multi-center, large sample, randomized, controlled trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025695

Enrollment

Unknown

Registered

2019-09-05

Start date

2019-09-05

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total joint arthroplasty

Interventions

A:iv TXA

B:No iv TXA

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Primary unilateral arthroplasty; 3. There is at least one risk factor for thrombosis: previous history of DVT, PE, myocardial infarction (MI), stroke (CVA), transient ischemic attack (TIA), post-coronary stenting, post-coronary artery bypass grafting, and hypercoagulable state of blood.

Exclusion criteria

Exclusion criteria: 1. Revision, unicondylar, hemiarthroplasty and hip surface replacement; 2. Recent joint infections; 3. General surgical contraindications; 4. Failure to cooperate with the completion of the test related indicators to assess patients.

Design outcomes

Secondary

Measure	Time frame
Hemoglobin level;Total bleeding volume;Length of hospitalization;Hospitalization expenses;	—

Primary

Measure	Time frame
Incidence of VTE within 3 months after operation;Blood transfusion rate;	—

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital, Sichuan University

zhouzongke@scu.edu.cn+86 18848329830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026